| Literature DB >> 32577634 |
Kizzmekia S Corbett1, Darin Edwards2, Sarah R Leist3, Olubukola M Abiona1, Seyhan Boyoglu-Barnum1, Rebecca A Gillespie1, Sunny Himansu2, Alexandra Schäfer3, Cynthia T Ziwawo1, Anthony T DiPiazza1, Kenneth H Dinnon3, Sayda M Elbashir2, Christine A Shaw2, Angela Woods2, Ethan J Fritch4, David R Martinez3, Kevin W Bock5, Mahnaz Minai5, Bianca M Nagata5, Geoffrey B Hutchinson1, Kapil Bahl2, Dario Garcia-Dominguez2, LingZhi Ma2, Isabella Renzi2, Wing-Pui Kong1, Stephen D Schmidt1, Lingshu Wang1, Yi Zhang1, Laura J Stevens6, Emily Phung7, Lauren A Chang1, Rebecca J Loomis1, Nedim Emil Altaras2, Elisabeth Narayanan2, Mihir Metkar2, Vlad Presnyak2, Catherine Liu1, Mark K Louder1, Wei Shi1, Kwanyee Leung1, Eun Sung Yang1, Ande West3, Kendra L Gully3, Nianshuang Wang8, Daniel Wrapp8, Nicole A Doria-Rose1, Guillaume Stewart-Jones2, Hamilton Bennett2, Martha C Nason9, Tracy J Ruckwardt1, Jason S McLellan8, Mark R Denison6, James D Chappell6, Ian N Moore5, Kaitlyn M Morabito1, John R Mascola1, Ralph S Baric3,4, Andrea Carfi2, Barney S Graham1.
Abstract
A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.Entities:
Year: 2020 PMID： 32577634 PMCID： PMC7301911 DOI： 10.1101/2020.06.11.145920
Source DB: PubMed Journal: bioRxiv